Transcriptomic profiles of tissues from rats treated with drug combinations [Study 1]

Combinations of anticancer agents may have synergistic anti-tumor effects, but enhanced toxicity often limit their clinical use. The risk that combinations of two or more drugs will cause adverse effects that are more severe than drugs used as monotherpies can be hypothesized from comprehensive analysis of each compound’s activity. We generated microarray gene expression data following a single dose of agents administered individually with that of the agents administered in a combination. The key objective of this initiative is to generate and make publicly available key high-content gene expression data sets for mechanistic hypothesis generation for several anticancer drug combinations. The expectation is that availability of tissue-based genomic information that are derived from target tissues will facilitate the generation and testing of mechanistic hypotheses. The view is that availability of these data sets for bioinformaticians and other scientists will contribute to analysis of these data and evaluation of the approach. Study 1 (originally study #3): Gene expression data from the bone marrow, heart and liver of Sprague-Dawley rats after after exposure to Temsirolimus at 0.3 mg/kg (i.v) or vehicle control (i.v) followed by either Sunitinib at 5 mg/kg (orally) or Sorafenib at 25 mg/kg (orally) or vehicle control (orally).